Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer

Cancer Science

Volumn 107, Issue 3, 2016, Pages 207-216

  Horinaka, Atsushi ^a   Sakurai, Daiju ^a   Ihara, Fumie ^a   Makita, Yuji ^a   Kunii, Naoki ^a   Motohashi, Shinichiro ^a   Nakayama, Toshinori ^a   Okamoto, Yoshitaka ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Head and neck cancer; Hydrogen peroxide; Immune suppression; Invariant NKT cell; Squamous cell carcinoma

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CATALASE; CD15 ANTIGEN; HYDROGEN PEROXIDE; FUCOSYLTRANSFERASE; FUT4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL ACTIVATION; CELL SUBPOPULATION; CELL VIABILITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; LYMPHOCYTE PROLIFERATION; MALE; MAXILLA SINUS CANCER; MOUTH CANCER; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER T CELL; OROPHARYNX CANCER; PRIORITY JOURNAL; SUPPRESSOR CELL; TONGUE CANCER; TUMOR DIFFERENTIATION; ADOPTIVE IMMUNOTHERAPY; BONE MARROW CELL; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; CELL PROLIFERATION; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD15; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL PROLIFERATION; FEMALE; FUCOSYLTRANSFERASES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; MYELOID CELLS; NATURAL KILLER T-CELLS;

EID: 84975705202     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12866     Document Type: Article

References (36)

1. Schuler G. Dendritic cells in cancer immunotherapy. Eur J Immunol 2010; 40: 2123-30.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
3. Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S. Immune suppression in head and neck cancers: a review. Clin Dev Immunol 2010; 2010: 701657.
4. Albers AE, Strauss L, Liao T, Hoffmann TK, Kaufmann AM. T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. Clin Dev Immunol 2010; 2010: 236378.
5. Goh C, Narayanan S, Hahn YS. Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunol Rev 2013; 255: 210-21.
6. Cripps JG, Gorham JD. MDSC in autoimmunity. Int Immunopharmacol 2011; 11: 789-93.
7. Filipazzi P, Valenti R, Huber V et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25: 2546-53.
8. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-506.
9. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-68.
10. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011; 60: 1419-30.
11. Solito S, Falisi E, Diaz-Montero CM et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011; 118: 2254-65.
12. Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012; 144: 250-68.
13. Vicari AP, Zlotnik A. Mouse NK1.1+ T cells: a new family of T cells. Immunol Today 1996; 17: 71-6.
14. Taniguchi M, Koseki H, Tokuhisa T et al. Essential requirement of an invariant Vα14 T cell antigen receptor expression in the development of natural killer T cells. Proc Natl Acad Sci USA 1996; 93: 11025-8.
15. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997; 15: 535-62.
16. Hameg A, Apostolou I, Leite-De-Moraes M et al. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen. J Immunol 2000; 165: 4917-26.
17. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626-9.
18. Brossay L, Chioda M, Burdin N et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998; 188: 1521-8.
19. Kawano T, Nakayama T, Kamada N et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 1999; 59: 5102-5.
20. Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci 2008; 99: 638-45.
21. Nieda M, Nicol A, Koezuka Y et al. TRAIL expression by activated human CD4(+) V alpha 24 NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 2001; 97: 2067-74.
22. Uchida T, Horiguchi S, Tanaka Y et al. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 2008; 57: 337-45.
23. Kunii N, Horiguchi S, Motohashi S et al. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 2009; 100: 1092-8.
24. Kurosaki M, Horiguchi S, Yamasaki K et al. Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer. Cancer Immunol Immunother 2011; 60: 207-15.
25. Yamasaki K, Horiguchi S, Kurosaki M et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 2011; 138: 255-65.
26. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
27. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16: 53-65.
28. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59: 1593-600.
29. Schouppe E, Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter JA. Modulation of CD8(+) T-cell activation events by monocytic and granulocytic myeloid-derived suppressor cells. Immunobiology 2013; 218: 1385-91.
30. Kusmartsev S, Su Z, Heiser A et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008; 14: 8270-8.
31. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172: 989-99.
32. Ando T, Mimura K, Johansson CC et al. Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J Immunol 2008; 181: 8382-90.
33. Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 2001; 11: 173-86.
34. Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA, Kang CY. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol 2009; 182: 1818-28.
35. De Santo C, Salio M, Masri SH et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest 2008; 118: 4036-48.
36. Fujii S, Shimizu K, Okamoto Y et al. NKT cells as an ideal anti-tumor immunotherapeutic. Front Immunol 2013; 4: 409.